8-K – 2025-08-06 – d90343d8k.htm

Fulltext

8-K

NY false 0001802768 0001802768 2025-08-06 2025-08-06
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 8-K
 
 

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2025
 
 

Royalty Pharma plc
(Exact Name of Registrant as Specified in its Charter)
 
 

 

England and Wales
 
001-39329
 
98-1535773

(State or other jurisdiction
of incorporation)
 
(Commission
File Number)

 
(I.R.S.
Identification No.)

 

 
110 East 59 th Street
 

 

 
New York , New York
 
10022
 

 
(Address of principal executive offices)
 
(Zip Code)
 

Registrant’s telephone number, including area code: (212) 883-0200
Not Applicable
(Former name or former address, if changed since last report)
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
 

Title of each class

 
Trading
symbol(s)

 
Name of each exchange
on which registered

Class A Ordinary Shares, par value $0.0001 per share
 
RPRX
 
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 

Item 2.02
Results of Operations and Financial Condition

On August 6, 2025, Royalty Pharma plc issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
 

Item 9.01
Financial Statements and Exhibits

(d) Exhibits
 

Exhibit
No.

  
Description

99.1
  
Press release issued by Royalty Pharma plc, dated August 6, 2025

104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 

 

 
ROYALTY PHARMA PLC

Date: August 6, 2025
 

 
By:
 
/s/ Terrance Coyne   

 

 

 
Terrance Coyne

 

 

 
Chief Financial Officer